Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-115226
Filing Date
2026-03-19
Accepted
2026-03-19 08:52:35
Documents
97
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K mreo-20251231.htm   iXBRL 10-K 3637333
2 EX-10.33 mreo-ex10_33.htm EX-10.33 38482
3 EX-23.1 mreo-ex23_1.htm EX-23.1 4355
4 EX-31.1 mreo-ex31_1.htm EX-31.1 26424
5 EX-31.2 mreo-ex31_2.htm EX-31.2 26448
6 EX-32.1 mreo-ex32_1.htm EX-32.1 8693
7 EX-32.2 mreo-ex32_2.htm EX-32.2 8661
8 GRAPHIC img262833_0.jpg GRAPHIC 196253
  Complete submission text file 0001193125-26-115226.txt   14158429

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20251231.xsd EX-101.SCH 1911983
101 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20251231_htm.xml XML 2373319
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON United Kingdom W1G 0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON United Kingdom W1G 0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38452 | Film No.: 26772566
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)